Fremont, California

Pictured above: Upstream process development in a high throughput automated bioreactor system.

Boehringer Ingelheim’s Fremont, California facility in the San Francisco Bay Area is the company’s U.S. biopharmaceutical manufacturing site. Established in 2011 and expanded in 2018, the facility is dedicated to the manufacture of monoclonal antibody medicines and other proteins from mammalian cell culture technology in 2,000 and 15,000 L scale.

Pictured above: Employees working in biopharmaceuticals upstream production.

The 300,000 square-foot facility features two trains with flexible commercial cell culture capacities, allowing for the simultaneous manufacturing of different small- and large-scale products. The site offers deep experience in N-1 perfusion process intensification technologies and is committed to manufacturing excellence. This dedication is further demonstrated by its commercial product track record, with more than five biologics successfully supplied to patients worldwide.

Vienna

Vienna, Austria, is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.

Biberach

The largest research and development center of Boehringer Ingelheim is located in Biberach, Germany. It is one of the largest sites in Europe for biopharmaceutical manufacturing.

Ingelheim

The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany. It is the largest site, serving both launch and commercial supply.

References